Four Years After One Infusion, a Gene Therapy Keeps Crigler-Najjar Syndrome in Check
Four years after a single infusion, a gene therapy for Crigler-Najjar syndrome is still keeping a toxic substance in check. In the New England Journal of Medicine on November 5, 2026, researchers from Généthon and their European partners reported long-term results for GNT0003, an AAV gene therapy that gives the liver a working copy of the UGT1A1 gene.
Of the three patients who received the therapeutic dose, two have stopped the daily phototherapy they had needed for most of their lives, and the third needs much less of it.

The patients this is for
Crigler-Najjar syndrome is a rare inherited liver disease. Normally, the liver enzyme UGT1A1 converts bilirubin, a yellow breakdown product of red blood cells, into a form the body can get rid of. People with Crigler-Najjar have little or no working UGT1A1, so bilirubin builds up in the blood.
Very high bilirubin can enter the brain and cause permanent damage. To prevent this, patients lie under special blue lights for 10 to 12 hours a day, usually overnight, because the light breaks bilirubin down through the skin. Phototherapy becomes less effective as children grow, and the only lasting option today is a liver transplant. About 500 people in Europe live with the disease.
How GNT0003 works
GNT0003 uses an AAV8 viral vector, which naturally travels to the liver, to deliver a working UGT1A1 gene in one intravenous infusion. Liver cells that take up the gene can then make the enzyme and clear bilirubin themselves.
The four-year results
The study, led in part by Dr. Lorenzo D'Antiga at the Papa Giovanni XXIII Hospital in Bergamo, Italy, with the patient group CureCN, followed patients for four years after treatment.
In all three patients at the therapeutic dose, bilirubin stayed below the level considered toxic to the brain.
Two of the three stopped phototherapy completely, and the third reduced it.
An early rise in liver enzymes after treatment resolved, and liver tests have stayed normal.
One patient went on to have a healthy pregnancy.

D'Antiga said the results "open a new path toward the correction of genetic liver diseases."
What to watch
A pivotal part of the trial began in January 2023 and includes patients aged 10 and older. The main question is whether the effect holds in more patients and over a longer time. Because AAV vectors mostly do not become part of the cell's DNA, the effect could fade as liver cells divide, which matters most for younger patients whose livers are still growing. Most people also develop antibodies after one AAV dose, which can make a second dose difficult.
GNT0003 would join a small but growing group of liver-directed AAV therapies, alongside approved gene therapies for hemophilia. Read our story on how one CRISPR infusion lowered triglycerides in people, another example of fixing a problem by treating the liver.
The bottom line
Four years after one infusion, a gene therapy for Crigler-Najjar syndrome kept bilirubin below toxic levels in all three treated patients and freed two of them from daily phototherapy. If the pivotal study confirms it, GNT0003 could offer an alternative to a lifetime under blue lights or a liver transplant.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Learn it properly: Gene Therapy 101 walks you from DNA to approved therapies in 8 animated modules with quizzes.
Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.
Read: The Life-Changing Power of Gene Therapy, real stories from the families behind the science.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times




Comments